Vargas M, Cardoso Toniasso S, Riedel P, Baldin C, Dos Reis F, Pereira R
World J Hepatol. 2024; 16(1):33-40.
PMID: 38313243
PMC: 10835488.
DOI: 10.4254/wjh.v16.i1.33.
Amanatidou A, Mikropoulou E, Amerikanou C, Milanovic M, Stojanoski S, Bjelan M
Metabolites. 2023; 13(8).
PMID: 37623902
PMC: 10456787.
DOI: 10.3390/metabo13080959.
Gangopadhyay A, Ibrahim R, Theberge K, May M, Houseknecht K
Front Neurosci. 2022; 16:1042442.
PMID: 36458039
PMC: 9707801.
DOI: 10.3389/fnins.2022.1042442.
Guveli H, Ovunc Kurdas O
Hepatol Forum. 2022; 3(2):45-50.
PMID: 35783474
PMC: 9243755.
DOI: 10.14744/hf.2022.2022.0004.
Albadawy R, Agwa S, Khairy E, Saad M, El Touchy N, Othman M
Biomedicines. 2021; 9(9).
PMID: 34572434
PMC: 8472260.
DOI: 10.3390/biomedicines9091248.
Noninvasive Diagnosis of NAFLD and NASH.
Piazzolla V, Mangia A
Cells. 2020; 9(4).
PMID: 32316690
PMC: 7226476.
DOI: 10.3390/cells9041005.
Characterizing Fatty Liver in vivo in Rabbits, Using Quantitative Ultrasound.
Nguyen T, Podkowa A, Tam A, Arnold E, Miller R, Park T
Ultrasound Med Biol. 2019; 45(8):2049-2062.
PMID: 31076231
PMC: 6591075.
DOI: 10.1016/j.ultrasmedbio.2019.03.021.
Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders.
Turchinovich A, Baranova A, Drapkina O, Tonevitsky A
Front Physiol. 2018; 9:1256.
PMID: 30294278
PMC: 6158334.
DOI: 10.3389/fphys.2018.01256.
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi Z, Loomba R, Anstee Q, Rinella M, Bugianesi E, Marchesini G
Hepatology. 2017; 68(1):349-360.
PMID: 29222917
PMC: 6511364.
DOI: 10.1002/hep.29721.
Nonalcoholic fatty liver disease: Diagnostic biomarkers.
Hadizadeh F, Faghihimani E, Adibi P
World J Gastrointest Pathophysiol. 2017; 8(2):11-26.
PMID: 28573064
PMC: 5437499.
DOI: 10.4291/wjgp.v8.i2.11.
Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.
Imajo K, Yoneda M, Fujita K, Kessoku T, Tomeno W, Ogawa Y
J Gastroenterol. 2013; 49(2):295-304.
PMID: 23503837
DOI: 10.1007/s00535-013-0776-3.
Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example.
Page S, Birerdinc A, Estep M, Stepanova M, Afendy A, Petricoin E
PLoS One. 2013; 8(2):e56009.
PMID: 23405244
PMC: 3566090.
DOI: 10.1371/journal.pone.0056009.
Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism.
Zhang Y, Baker S, Baker R, Zhu R, Zhu L
PLoS One. 2013; 7(12):e51131.
PMID: 23300535
PMC: 3530598.
DOI: 10.1371/journal.pone.0051131.
Resistin expression correlates with steatohepatitis in morbidly obese patients.
Edwards C, Hindle A, Latham P, Fu S, Brody F
Surg Endosc. 2012; 27(4):1310-4.
PMID: 23233000
DOI: 10.1007/s00464-012-2603-y.
A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
Younossi Z, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N
Obes Surg. 2010; 21(4):431-9.
PMID: 20532833
DOI: 10.1007/s11695-010-0204-1.
Non alcoholic fatty liver disease and metabolic syndrome.
Paschos P, Paletas K
Hippokratia. 2009; 13(1):9-19.
PMID: 19240815
PMC: 2633261.
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Vuppalanchi R, Chalasani N
Hepatology. 2008; 49(1):306-17.
PMID: 19065650
PMC: 2766096.
DOI: 10.1002/hep.22603.
